Limits...
Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus

Histological analysis of inflammation and demyelination. (A–D) H&E staining. Magnification, ×200; (E–H) LFB staining. Magnification, ×5; (A and E) naive group; (B and F) vehicle group; (C and G) TSIIA-L group; (D and H) TSIIA-H group. (I) Quantification of inflammatory cell infiltration (H&E staining, A–D), (J) demyelination quantification (LFB staining, E–H). Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, compared with the TSIIA-H group. TSIIA, Tanshinone IIA; LFB, Luxol Fast Blue; H&E, hematoxylin and eosin.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4940100&req=5

f2-mmr-14-02-1601: Histological analysis of inflammation and demyelination. (A–D) H&E staining. Magnification, ×200; (E–H) LFB staining. Magnification, ×5; (A and E) naive group; (B and F) vehicle group; (C and G) TSIIA-L group; (D and H) TSIIA-H group. (I) Quantification of inflammatory cell infiltration (H&E staining, A–D), (J) demyelination quantification (LFB staining, E–H). Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, compared with the TSIIA-H group. TSIIA, Tanshinone IIA; LFB, Luxol Fast Blue; H&E, hematoxylin and eosin.

Mentions: Since inflammatory cell invasion and CNS demyelination are the key characteristics of EAE, the impact of TSIIA on these parameters was verified. Consistent with clinical scores, rats in the vehicle group exhibited typical inflammatory cell infiltration in the brain, as determined via H&E staining. This cell infiltration was dose dependently attenuated following TSIIA treatment (Fig. 2A). Similarly, LFB staining revealed large areas of demyelination in the spinal cord of rats from the vehicle group, which were significantly decreased in the treated groups (both P<0.01; Fig. 2B). These results clearly indicate a beneficial effect of TSIIA in reducing inflammatory cell infiltration and demyelination, which provide the basement of mitigated clinical signs following TSIIA treatment.


Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats.

Yan J, Yang X, Han D, Feng J - Mol Med Rep (2016)

Histological analysis of inflammation and demyelination. (A–D) H&E staining. Magnification, ×200; (E–H) LFB staining. Magnification, ×5; (A and E) naive group; (B and F) vehicle group; (C and G) TSIIA-L group; (D and H) TSIIA-H group. (I) Quantification of inflammatory cell infiltration (H&E staining, A–D), (J) demyelination quantification (LFB staining, E–H). Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, compared with the TSIIA-H group. TSIIA, Tanshinone IIA; LFB, Luxol Fast Blue; H&E, hematoxylin and eosin.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4940100&req=5

f2-mmr-14-02-1601: Histological analysis of inflammation and demyelination. (A–D) H&E staining. Magnification, ×200; (E–H) LFB staining. Magnification, ×5; (A and E) naive group; (B and F) vehicle group; (C and G) TSIIA-L group; (D and H) TSIIA-H group. (I) Quantification of inflammatory cell infiltration (H&E staining, A–D), (J) demyelination quantification (LFB staining, E–H). Values are presented as the mean ± standard deviation (n=10 per group). ΔP<0.01, compared with the naive group; *P<0.01, compared with the vehicle group; #P<0.01, compared with the TSIIA-H group. TSIIA, Tanshinone IIA; LFB, Luxol Fast Blue; H&E, hematoxylin and eosin.
Mentions: Since inflammatory cell invasion and CNS demyelination are the key characteristics of EAE, the impact of TSIIA on these parameters was verified. Consistent with clinical scores, rats in the vehicle group exhibited typical inflammatory cell infiltration in the brain, as determined via H&E staining. This cell infiltration was dose dependently attenuated following TSIIA treatment (Fig. 2A). Similarly, LFB staining revealed large areas of demyelination in the spinal cord of rats from the vehicle group, which were significantly decreased in the treated groups (both P<0.01; Fig. 2B). These results clearly indicate a beneficial effect of TSIIA in reducing inflammatory cell infiltration and demyelination, which provide the basement of mitigated clinical signs following TSIIA treatment.

Bottom Line: Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown.Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents.The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.

ABSTRACT
Multiple sclerosis (MS) is an inflammatory autoimmune neurodegenerative disease, which features focal demyelination and inflammatory cell infiltration of the brain and the spinal cord. Tanshinone IIA (TSIIA), one of the major fat‑soluble components of Salvia miltiorrhiza (Danshen), has anti‑inflammatory, immunoregulatory and neuroprotective activity; however, its efficacy in MS remains unknown. The current study was designed to investigate the potential therapeutic function of TSIIA on MS in the experimental autoimmune encephalomyelitis (EAE) rat model. In comparison to the vehicle control group, the TSIIA‑treated groups showed notably improved clinical symptoms and pathological changes, including central nervous system inflammatory cell infiltration and demyelination. Following administration of TSIIA, the quantity of CD4+ T cells, CD8+ T cells and macrophages/microglia in the spinal cord were reduced to different extents. Furthermore, TSIIA was also shown to downregulate interleukin (IL)‑17 and IL‑23 levels in the brain and serum of EAE rats. The results collectively provide evidence that TSIIA alleviates EAE and support its utility as a novel therapy for MS.

No MeSH data available.


Related in: MedlinePlus